查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
神经血管设备市场:产业趋势与世界预测 (～2035年)- 不同设备类型，各治疗用途，各终端用户，各主要地区，各主要企业
市场调查报告书
商品编码
1549408

神经血管设备市场:产业趋势与世界预测 (～2035年)- 不同设备类型，各治疗用途，各终端用户，各主要地区，各主要企业

Global Neurovascular Devices Market: Industry Trends and Global Forecasts, till 2035: Distribution by Type of Device, Therapeutic Application, End Users, Key Geographical Regions and Key Leading Players
出版日期: | 出版商: Roots Analysis | 英文 255 Pages | 商品交期: 最快1-2个工作天内

价格

2024年全球神经血管器械市场规模预估为33.25亿美元，2024-2035年预测期间复合年增长率为7.02%。

神经血管疾病是一类神经系统疾病，其特征是流向大脑、脊髓和周边神经的血流受损。这种疾病通常是由大脑血管问题引起的，例如阻塞（栓塞）、破裂（出血）、血栓（血栓）或狭窄（狭窄）。这些疾病导致大脑氧气和营养供应不足，导致细胞死亡（细胞凋亡），从而导致永久性的身体和精神残疾。值得注意的是，神经血管疾病是全球排名前五的威胁生命的疾病之一，给各个地区带来了巨大的经济负担。据世界卫生组织 (WHO) 称，这些疾病每年在全球造成约 1500 万新病例和 500 万人死亡。导致神经血管疾病发生和盛行率增加的因素包括不健康的生活习惯、身体创伤、营养不良、脑损伤和先天性异常。

目前，几种传统的手术方法被用来治疗神经血管疾病，包括开颅手术、显微手术、开颅手术和搭桥手术。然而，这些方法由于其复杂性、耗时、成功率低、恢復期长以及需要专家监督和专门手术中心而具有局限性。为了克服这些挑战，神经血管装置已成为一种有前景的替代治疗方法。这些仪器提供精确、有针对性、微创的介入技术。例如，颅内支架、栓塞弹簧圈、分流器、导丝和导管，这些产品专为血流减少的大脑区域进行特定部位的显微手术而设计。这些技术进步使神经血管装置被视为神经血管疾病的创新治疗选择。由于持续的研究、技术创新和投资者兴趣的不断增长，神经血管设备市场预计在未来几年将显着增长。

该市场的成长也带动了神经血管设备涂层等相关产业的发展。 Biocoat 等公司为各种医疗设备提供专业涂层，包括神经血管设备的客製化涂层。此外，许多医疗器材合约製造商为神经血管器材领域的公司提供设计、开发和製造服务。

本报告提供全球神经血管设备市场相关调查，提供市场概要，以及不同设备类型，各治疗用途，各终端用户，各主要地区的趋势，及加入此市场的主要企业简介等资讯。

目录

第1章 序文

第2章 调查手法

第3章 经济以及其他的计划特有的考虑事项

第4章 摘要整理

第5章 简介

第6章 市场形势

第7章 企业简介

  • 章概要
  • Johnson &Johnson
  • Medtronic
  • MicroVention
  • Penumbra
  • Stryker
  • 其他的企业

第8章 产品竞争力分析

第9章 伙伴关係和合作

第10章 资金筹措与投资

第11章 需求分析

第12章 对市场的影响分析:促进因素，阻碍因素，机会，课题

第13章 全球神经血管设备市场

第14章 神经血管设备市场(不同设备类型)

第15章 神经血管设备市场(各治疗用途)

第16章 神经血管设备市场(各终端用户)

第17章 神经血管设备市场(各主要地区)

第18章 神经血管设备市场(主要加入企业)

第19章 结论

第20章 附录1:表格形式的资料

第21章 附录2:企业·团体一览

Product Code: RA100508

The Global Neurovascular Devices Market is valued at USD 3,325 million in 2024 growing at a CAGR of 7.02% during the forecast period 2024-2035.

Neurovascular disorders are a category of neurological conditions characterized by impaired blood flow to the brain, spinal cord, and peripheral nerves. This disruption is often caused by issues with cerebral blood vessels, including blockages (embolism), ruptures (hemorrhage), clots (thrombosis), or narrowing (stenosis). Such disruptions result in insufficient oxygen and nutrient supply to the brain, leading to cell death (apoptosis) and subsequent permanent physical and mental impairments. Notably, neurovascular disorders rank among the top five life-threatening conditions worldwide, imposing a significant economic burden across various regions. According to the World Health Organization, these disorders lead to approximately 15 million new cases and five million deaths globally each year. Contributing factors to the development and increasing prevalence of neurovascular disorders include unhealthy lifestyles, physical trauma, malnutrition, brain injuries, and congenital abnormalities.

Currently, several traditional surgical approaches are employed to treat neurovascular disorders, such as open neurosurgery, microsurgery, craniotomy, and bypass surgery. However, these methods have limitations due to their complexity, time-intensive procedures, lower success rates, prolonged recovery periods, and the need for expert supervision and specialized surgical centers. To overcome these challenges, neurovascular devices have emerged as a promising treatment alternative. These devices offer precise, targeted, and minimally invasive interventional techniques. Examples include intracranial stents, embolic coils, flow diverters, guidewires, and catheters, which are designed for site-specific microsurgery in areas of the brain with compromised blood flow. Due to these technological advancements, neurovascular devices are now considered innovative treatment options for neurovascular disorders. With ongoing research, innovation, and growing investor interest, the neurovascular devices market is expected to experience substantial growth in the coming years.

This market growth is also driving developments in related industries, such as the coating of neurovascular devices. Companies like Biocoat are providing specialized coatings for various medical devices, including custom coatings for neurovascular devices. Additionally, numerous medical device contract manufacturers are offering design, development, and production services to companies in the neurovascular device sector.

Key Market Segments

Type of Device

  • Neurothrombectomy Devices
  • Embolization Devices
  • Angioplasty Devices

Therapeutic Application

  • Ischemic Stroke
  • Aneurysm
  • Stenosis
  • Arteriovenous Malformations (AVMs)

End Users

  • Hospitals and Specialty Clinics
  • Ambulatory Care Centers
  • Other End Users

Key Geographical Regions

  • North America
  • Europe
  • Asia-Pacific
  • Middle East and North Africa
  • Latin America

Key Leading Players

  • Integer Holdings
  • Johnson & Johnson
  • Medtronic Inc.
  • MicroVention
  • Penumbra Inc.
  • Shanghai HeartCare Medical Technology
  • Stryker Corporation

Research Coverage:

  • This report provides a general overview of the neurovascular disorders, featuring details on different types of neurovascular disorders along with the historical evolution of their treatment approaches. Further, it also projects information on the current scenario of treatment options for neurovascular disorders along with the types of neurovascular devices. Further, it features the recent advancements, challenges and future outlook associated with the neurovascular devices.
  • Comprehensive outlook of the current market landscape of neurovascular device developers, along with information on their status of development (approved, commercialized and under development), type of device (accessory devices (catheters, guidewires and other accessory devices), angioplasty devices (revascularization, balloon occlusion devices and embolic protection systems) embolization devices (embolic coils / clippings, stent-assisted devices and other embolization devices), and neurothrombectomy devices (clot retrieval devices, aspiration / suction devices and other thrombectomy devices), therapeutic application (ischemic stroke, hemorrhagic stroke, aneurysms, arteriovenous malformations, arteriovenous fistulae, stenosis and others), material of fabrication and coating material of device. Further, this chapter provides an overview of the developers engaged in developing these devices, featuring a comprehensive analysis across several relevant parameters, such as their establishment year, company size (based on the employee count), location of headquarters. Moreover, this section also presents the most active players based on the number of neurovascular devices offered.
  • Comprehensive company profiles of neurovascular device developers, featuring information on their year of establishment, location of headquarters, employee count, leadership team, financial information (if available), neurovascular device portfolio, recent developments and an informed future outlook.
  • Comprehensive competitiveness analysis of the neurovascular devices across several relevant parameters, such as strength of the company (in terms of years of experience and company size), product portfolio strength (in terms of type of device, its status of development, region of approval, material of fabrication and coating material of device) and product portfolio diversity (number of therapeutic application).
  • In-depth analysis of various partnerships and collaborations inked in the global neurovascular devices market between the stakeholders since 2019, across prominent parameters, such as year of the partnership, type of the partnership, type of the partner, type of device, therapeutic application, most active players (in terms of number of partnerships inked) and geographical analysis.
  • Elaborate analysis of the funding and investments activity registered in the neurovascular device companies since 2019, including grants, private placement offerings, capital raised from seed financing, debt financing, venture series and other equity, at various stages of the device development. The funding and investments made by the stakeholders, were analyzed based on several relevant parameters, such as year-wise trend of the funding instances, type of funding, month and year of funding, total amount invested, geographical analysis of the funding and the investment, leading players (in terms of number of funding instances and amount raised) and investors (in terms of number of funding instances).
  • An in-depth analysis in order to analyze the current and future demand for neurovascular devices, on the basis of several relevant parameters, such as type of device (neurothrombectomy devices, embolization devices and angioplasty devices), therapeutic application (ischemic stroke, aneurysm, stenosis and arteriovenous malformations (AVMs)), key geographical regions (North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America) and key leading players, till 2035.
  • An in-depth analysis of the factors that can affect the growth of the neurovascular devices market. It features identification and analysis of key market drivers, potential market restraints, emerging opportunities in the market, and existing challenges encountered in the market.
  • A detailed estimate of the current neurovascular devices market size and the future growth potential for neurovascular medical device developers over the next decade. Based on the multiple parameters, such as likely adoption of the trends and via reliable secondary and primary validations, we have projected an informed estimate on the market evolution during the forecast period till 2035. The report also features the likely distribution of the current and forecasted opportunity within the neurovascular devices industry. Further, in order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of the market growth.
  • Comprehensive predictions of the current and future opportunity for neurovascular device developers in the market based on various types of devices, such as neurothrombectomy devices, embolization devices and angioplasty devices.
  • Comprehensive projections of the current and future opportunity within the neurovascular devices market based on different therapeutic applications, such as ischemic stroke, aneurysm, stenosis and arteriovenous malformations (AVMs).
  • Comprehensive projections of the current and future opportunity for neurovascular device developers in the market based on various end users, such as hospitals and specialty clinics, ambulatory care centers and other end users.
  • Comprehensive projections of the current and future opportunity for neurovascular device developers in the market across key geographical regions, such as North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America.
  • Comprehensive predictions of the current revenues of the leading players in the neurovascular device domain, which includes Integer Holdings, Johnson & Johnson, Medtronic Inc., MicroVention, Penumbra Inc., Shanghai HeartCare Medical Technology and Stryker Corporation.

Key Benefits of Buying this Report

  • The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.
  • Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.
  • The report provides stakeholders with a pulse on the Global Neurovascular Devices Market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.

Leading Market Companies

  • Acandis
  • Achieva Medical
  • Balt
  • HeMo Bioengineering
  • Johnson & Johnson
  • Medtronic Inc.
  • MicroVention
  • Penumbra Inc.
  • Phenox
  • Shanghai HeartCare Medical Technology
  • Stryker Corporation
  • Zylox-Tonbridge

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Introduction
  • 1.2. Market Share Insights
  • 1.3. Key Market Insights
  • 1.4. Report Coverage
  • 1.5. Key Questions Answered
  • 1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

  • 2.1. Chapter Overview
  • 2.2. Research Assumptions
    • 2.2.1. Market Landscape and Market Trends
    • 2.2.2. Market Forecast and Opportunity Analysis
    • 2.2.3. Comparative Analysis
  • 2.3. Database Building
    • 2.3.1. Data Collection
    • 2.3.2. Data Validation
    • 2.3.3. Data Analysis
  • 2.4. Project Methodology
    • 2.4.1. Secondary Research
      • 2.4.1.1. Annual Reports
      • 2.4.1.2. Academic Research Papers
      • 2.4.1.3. Company Websites
      • 2.4.1.4. Investor Presentations
      • 2.4.1.5. Regulatory Filings
      • 2.4.1.6. White Papers
      • 2.4.1.7. Industry Publications
      • 2.4.1.8. Conferences and Seminars
      • 2.4.1.9. Government Portals
      • 2.4.1.10. Media and Press Releases
      • 2.4.1.11. Newsletters
      • 2.4.1.12. Industry Databases
      • 2.4.1.13. Roots Proprietary Databases
      • 2.4.1.14. Paid Databases and Sources
      • 2.4.1.15. Social Media Portals
      • 2.4.1.16. Other Secondary Sources
    • 2.4.2. Primary Research
      • 2.4.2.1. Types of Primary Research
        • 2.4.2.1.1. Qualitative Research
        • 2.4.2.1.2. Quantitative Research
        • 2.4.2.1.3. Hybrid Approach
      • 2.4.2.2. Advantages of Primary Research
      • 2.4.2.3. Techniques for Primary Research
        • 2.4.2.3.1. Interviews
        • 2.4.2.3.2. Surveys
        • 2.4.2.3.3. Focus Groups
        • 2.4.2.3.4. Observational Research
        • 2.4.2.3.5. Social Media Interactions
      • 2.4.2.4. Key Opinion Leaders Considered in Primary Research
        • 2.4.2.4.1. Company Executives (CXOs)
        • 2.4.2.4.2. Board of Directors
        • 2.4.2.4.3. Company Presidents and Vice Presidents
        • 2.4.2.4.4. Research and Development Heads
        • 2.4.2.4.5. Technical Experts
        • 2.4.2.4.6. Subject Matter Experts
        • 2.4.2.4.7. Scientists
        • 2.4.2.4.8. Doctors and Other Healthcare Providers
      • 2.4.2.5. Ethics and Integrity
        • 2.4.2.5.1. Research Ethics
        • 2.4.2.5.2. Data Integrity
    • 2.4.3. Analytical Tools and Databases

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

  • 3.1. Chapter Overview
  • 3.2. Market Dynamics
    • 3.2.1. Time Period
      • 3.2.1.1. Historical Trends
      • 3.2.1.2. Current and Future Estimates
    • 3.2.2. Currency Coverage and Foreign Exchange Rate
      • 3.2.2.1. Major Currencies Affecting the Market
      • 3.2.2.2. Factors Affecting Currency Fluctuations and Foreign Exchange Rate
      • 3.2.2.3. Impact of Foreign Exchange Rate Volatility on the Market
      • 3.2.2.4. Strategies for Mitigating Foreign Exchange Risk
    • 3.2.3. Trade Policies
      • 3.2.3.1. Impact of Trade Barriers on the Market
      • 3.2.3.2. Strategies for Mitigating the Risk Associated with Trade Barriers
    • 3.2.4. Recession
      • 3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
      • 3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
    • 3.2.5. Inflation
      • 3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
      • 3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

5. INTRODUCTION

  • 5.1. Chapter Overview
  • 5.2. Neurovascular Disorders
  • 5.3. Historical Milestones in the Neurovascular Disorders Treatment
  • 5.4. Treatment of Neurovascular Disorders
  • 5.5. Types of Neurovascular Devices
  • 5.6. Recent Advancements in Neurovascular Devices
  • 5.7. Challenges Associated with Neurovascular Devices
  • 5.8. Future Perspectives

6. MARKET LANDSCAPE

  • 6.1. Chapter Overview
  • 6.2. Neurovascular Devices Market: Overall Market Landscape
    • 6.2.1. Analysis by Status of Development
    • 6.2.2. Analysis by Type of Device
    • 6.2.3. Analysis by Therapeutic Application
    • 6.2.4. Analysis by Type of Device and Therapeutic Application
    • 6.2.5. Analysis by Material of Fabrication
    • 6.2.6. Analysis by Coating Material of Device
  • 6.3. Neurovascular Devices Market: Developer Landscape
    • 6.3.1. Analysis by Year of Establishment
    • 6.3.2. Analysis by Company Size
    • 6.3.3. Analysis by Location of Headquarters (Region)
    • 6.3.4. Analysis by Location of Headquarters (Country)
    • 6.3.5. Analysis by Company Size and Location of Headquarters (Region)
    • 6.3.6. Most Active Developers: Analysis by Number of Neurovascular Devices Developed

7. COMPANY PROFILES

  • 7.1. Chapter Overview
  • 7.2. Johnson & Johnson
    • 7.2.1. Company Overview
    • 7.2.2. Financial Information
    • 7.2.3. Neurovascular Device Portfolio
    • 7.2.4. Recent Developments and Future Outlook
  • 7.3. Medtronic
    • 7.3.1. Company Overview
    • 7.3.2. Financial Information
    • 7.3.3. Neurovascular Device Portfolio
    • 7.3.4. Recent Developments and Future Outlook
  • 7.4. MicroVention
    • 7.4.1. Company Overview
    • 7.4.2. Financial Information
    • 7.4.3. Neurovascular Device Portfolio
    • 7.4.4. Recent Developments and Future Outlook
  • 7.5. Penumbra
    • 7.5.1. Company Overview
    • 7.5.2. Financial Information
    • 7.5.3. Neurovascular Device Portfolio
    • 7.5.4. Recent Developments and Future Outlook
  • 7.6. Stryker
    • 7.6.1. Company Overview
    • 7.6.2. Financial Information
    • 7.6.3. Neurovascular Device Portfolio
    • 7.6.4. Recent Developments and Future Outlook
  • 7.7. Other Leading Players
    • 7.7.1. Acandis
      • 7.7.1.1. Company Overview
      • 7.7.1.2. Neurovascular Device Portfolio
    • 7.7.2. Achieva Medical
      • 7.7.2.1. Company Overview
      • 7.7.2.2. Neurovascular Device Portfolio
    • 7.7.3. Balt
      • 7.7.3.1. Company Overview
      • 7.7.3.2. Neurovascular Device Portfolio
    • 7.7.4. HeMo Bioengineering
      • 7.7.4.1. Company Overview
      • 7.7.4.2. Neurovascular Device Portfolio
    • 7.7.5. Phenox
      • 7.7.5.1. Company Overview
      • 7.7.5.2. Neurovascular Device Portfolio
    • 7.7.6. Shanghai HeartCare Medical Technology
      • 7.7.6.1. Company Overview
      • 7.7.6.2. Neurovascular Device Portfolio
    • 7.7.7. Zylox-Tonbridge
      • 7.7.7.1. Company Overview
      • 7.7.7.2. Neurovascular Device Portfolio

8. PRODUCT COMPETITIVENESS ANALYSIS

  • 8.1. Chapter Overview
  • 8.2. Assumptions and Key Parameters
  • 8.3. Methodology
  • 8.4. Product Competitiveness Analysis: Analysis by Location of Headquarters of Neurovascular Device Developers
    • 8.4.1. Product Competitiveness Analysis: Neurovascular Devices Developed by Players based in North America
    • 8.4.2. Product Competitiveness Analysis: Neurovascular Devices Developed by Players based in Europe
    • 8.4.3. Product Competitiveness Analysis: Neurovascular Devices Developed by Players based in Asia-Pacific and Rest of the World

9. PARTNERSHIPS AND COLLABORATIONS

  • 9.1. Chapter Overview
  • 9.2. Partnership Models
  • 9.3. Neurovascular Devices Market: Partnerships and Collaborations
    • 9.3.1. Analysis by Year of Partnership
    • 9.3.2. Analysis by Type of Partnership
    • 9.3.3. Analysis by Year and Type of Partnership
    • 9.3.4. Analysis by Type of Partner
    • 9.3.5. Analysis by Year of Partnership and Type of Partner
    • 9.3.6. Analysis by Type of Partnership and Type of Partner
    • 9.3.7. Analysis by Type of Device
    • 9.3.8. Analysis by Therapeutic Application
    • 9.3.9. Most Active Players: Analysis by Number of Partnerships
    • 9.3.10. Analysis by Geography
      • 9.3.10.1. Local and International Agreements
      • 9.3.10.2. Intracontinental and Intercontinental Agreements

10. FUNDING AND INVESTMENTS

  • 10.1. Chapter Overview
  • 10.2. Funding Models
  • 10.3. Neurovascular Devices Market: Funding and Investments
    • 10.3.1. Analysis by Year of Funding
    • 10.3.2. Analysis by Type of Funding
    • 10.3.3. Analysis by Year and Type of Funding
    • 10.3.4. Analysis by Amount Invested
    • 10.3.5. Analysis of Amount Invested by Type of Funding
    • 10.3.6. Analysis by Geography
    • 10.3.7. Most Active Players: Analysis by Number of Funding Instances
    • 10.3.8. Most Active Players: Analysis by Amount Raised
    • 10.3.9. Leading Investors: Analysis by Number of Funding Instances
  • 10.4. Concluding Remarks

11. DEMAND ANALYSIS

  • 11.1. Chapter Overview
  • 11.2. Assumptions and Methodology
  • 11.3. Neurovascular Devices: Global Annual Demand
    • 11.3.1. Analysis by Type of Device
    • 11.3.2. Analysis by Therapeutic Application
    • 11.3.3. Analysis by Key Geographical Regions

12. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

  • 12.1. Chapter Overview
  • 12.2. Market Drivers
  • 12.3. Market Restraints
  • 12.4. Market Opportunities
  • 12.5. Market Challenges
  • 12.6. Conclusion

13. GLOBAL NEUROVASCULAR DEVICES MARKET

  • 13.1. Chapter Overview
  • 13.2. Key Assumptions and Methodology
  • 13.3. Global Neurovascular Devices Market, till 2035
    • 13.3.1. Scenario Analysis
      • 13.3.1.1. Conservative Scenario
      • 13.3.1.2. Optimistic Scenario
  • 13.4. Key Market Segmentations

14. NEUROVASCULAR DEVICES MARKET, BY TYPE OF DEVICE

  • 14.1. Chapter Overview
  • 14.2. Key Assumptions and Methodology
  • 14.3. Neurovascular Devices Market: Distribution by Type of Device, 2019, current year and 2035
  • 14.4. Neurovascular Devices Market for Neurothrombectomy Devices, till 2035
  • 14.5. Neurovascular Devices Market for Embolization Devices, till 2035
  • 14.6. Neurovascular Devices Market for Angioplasty Devices, till 2035
  • 14.7. Data Triangulation and Validation

15. NEUROVASCULAR DEVICES MARKET, BY THERAPEUTIC APPLICATION

  • 15.1. Chapter Overview
  • 15.2. Key Assumptions and Methodology
  • 15.3. Neurovascular Devices Market: Distribution by Therapeutic Application, 2019, current year and 2035
  • 15.4. Neurovascular Devices Market for Ischemic Stroke, till 2035
  • 15.5. Neurovascular Devices Market for Aneurysm, till 2035
  • 15.6. Neurovascular Devices Market for Stenosis, till 2035
  • 15.7. Neurovascular Devices Market for Arteriovenous Malformations (AVMs), till 2035
  • 15.8. Data Triangulation and Validation

16. NEUROVASCULAR DEVICES MARKET, BY END-USERS

  • 16.1. Chapter Overview
  • 16.2. Key Assumptions and Methodology
  • 16.3. Neurovascular Devices Market: Distribution by End-users, 2019, current year and 2035
  • 16.4. Neurovascular Devices Market for Hospitals and Specialty Clinics, till 2035
  • 16.5. Neurovascular Devices Market for Ambulatory Care Centers, till 2035
  • 16.6. Neurovascular Devices Market for Other End-users, till 2035
  • 16.7. Data Triangulation and Validation

17. NEUROVASCULAR DEVICES MARKET, BY KEY GEOGRAPHICAL REGIONS

  • 17.1. Chapter Overview
  • 17.2. Key Assumptions and Methodology
  • 17.3. Neurovascular Devices Market: Distribution by Key Geographical Regions, 2019, current year and 2035
  • 17.4. Neurovascular Devices Market in North America, till 2035
  • 17.5. Neurovascular Devices Market in Europe, till 2035
  • 17.6. Neurovascular Devices Market in Asia-Pacific, till 2035
  • 17.7. Neurovascular Devices Market in Middle East and North Africa, till 2035
  • 17.8. Neurovascular Devices Market in Latin America, till 2035
  • 17.9. Data Triangulation and Validation

18. Neurovascular devices MARKET: KEY Leading players

  • 18.1. Chapter Overview
  • 18.2. Key Assumptions and Methodology
  • 18.3. Neurovascular Devices Market: Distribution by Key Leading Players
  • 18.4. Data Triangulation and Validation

19. CONCLUSION

20. APPENDIX 1: TABULATED DATA

21. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATION

List of Tables

  • Table 6.1 Neurovascular Devices Market: Information on Developer, Status of Development, Region of Approval, Type of Device, Shelf Life and Method of Sterilization
  • Table 6.2 Neurovascular Devices: Information on Therapeutic Application, Material of Fabrication, Coating Material of Device, Working Length, Full Length and Outer Diameter
  • Table 6.3 Neurovascular Devices: List of Developers
  • Table 7.1 List of Companies: Detailed Profiles
  • Table 7.2 Johnson & Johnson: Company Overview
  • Table 7.3 Johnson & Johnson: Neurovascular Device Portfolio
  • Table 7.4 Johnson & Johnson: Recent Developments and Future Outlook
  • Table 7.5 Medtronic: Company Overview
  • Table 7.6 Medtronic: Neurovascular Device Portfolio
  • Table 7.7 Medtronic: Recent Developments and Future Outlook
  • Table 7.8 MicroVention: Company Overview
  • Table 7.9 MicroVention: Neurovascular Device Portfolio
  • Table 7.10 Penumbra: Company Overview
  • Table 7.11 Penumbra: Neurovascular Device Portfolio
  • Table 7.12 Stryker: Company Overview
  • Table 7.13 Stryker: Neurovascular Devices Portfolio
  • Table 7.14 Stryker: Recent Developments and Future Outlook
  • Table 7.15 List of Companies: Short Profiles
  • Table 7.16 Acandis: Company Overview
  • Table 7.17 Acandis: Neurovascular Device Portfolio
  • Table 7.18 Achieva Medical: Company Overview
  • Table 7.19 Achieva Medical: Neurovascular Device Portfolio
  • Table 7.20 Balt: Company Overview
  • Table 7.21 Balt: Neurovascular Device Portfolio
  • Table 7.22 HeMo Bioengineering: Company Overview
  • Table 7.23 HeMo Bioengineering: Neurovascular Device Portfolio
  • Table 7.24 Phenox: Company Overview
  • Table 7.25 Phenox: Neurovascular Device Portfolio
  • Table 7.26 Shanghai HeartCare Medical Technology: Company Overview
  • Table 7.27 Shanghai Heartcare Medical Technology: Neurovascular Device Portfolio
  • Table 7.28 Zylox-Tonbridge: Company Overview
  • Table 7.29 Zylox-Tonbridge: Neurovascular Device Portfolio
  • Table 9.1 Neurovascular Devices Market: List of Partnerships and Collaborations, Since 2019
  • Table 9.2 Partnerships and Collaborations: Information on Location of Headquarters (Country and Region) and Type of Agreement (Country and Region)
  • Table 10.1 Neurovascular Devices: List of Funding and Investments, Since 2019
  • Table 20.1 Neurovascular Devices: Distribution by Status of Development
  • Table 20.2 Neurovascular Devices: Distribution by Type of Device
  • Table 20.3 Neurovascular Devices: Distribution by Therapeutic Application
  • Table 20.4 Neurovascular Devices: Distribution by Type of Device and Therapeutic Application
  • Table 20.5 Neurovascular Devices: Distribution by Material of Fabrication
  • Table 20.6 Neurovascular Devices: Distribution by Coating Material of Device
  • Table 20.7 Neurovascular Device Developers: Distribution by Year of Establishment
  • Table 20.8 Neurovascular Device Developers: Distribution by Company Size
  • Table 20.9 Neurovascular Device Developers: Distribution by Location of Headquarters (Region)
  • Table 20.10 Neurovascular Device Developers: Distribution by Location of Headquarters (Country)
  • Table 20.11 Neurovascular Device Developers: Distribution by Company Size and Location of Headquarters (Region)
  • Table 20.12 Most Active Developers: Distribution by Number of Neurovascular Devices Developed
  • Table 20.13 Johnson & Johnson: Annual Revenues, FY 2020 Onwards (USD Million)
  • Table 20.14 Medtronic: Annual Revenues, FY 2020 Onwards (USD Billion)
  • Table 20.15 MicroVention: Annual Revenues, FY 2020 Onwards (Yen Billion)
  • Table 20.16 Penumbra: Annual Revenues, FY 2019 Onwards (USD Million)
  • Table 20.17 Stryker: Annual Revenues, FY 2019 Onwards (USD Billion)
  • Table 20.18 Partnerships and Collaborations: Cumulative Year-wise Trend, Since 2019
  • Table 20.19 Partnerships and Collaborations: Distribution by Type of Partnership
  • Table 20.20 Partnerships and Collaborations: Distribution by Year and Type of Partnership, Since 2019
  • Table 20.21 Partnerships and Collaborations: Distribution by Type of Partner
  • Table 20.22 Partnerships and Collaborations: Distribution by Year and Type of Partner, Since 2019
  • Table 20.23 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
  • Table 20.24 Partnerships and Collaborations: Distribution by Type of Device
  • Table 20.25 Partnerships and Collaborations: Distribution by Therapeutic Application
  • Table 20.26 Most Active Players: Distribution by Number of Partnerships
  • Table 20.27 Partnerships and Collaborations: Local and International Agreements
  • Table 20.28 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
  • Table 20.29 Funding and Investments: Cumulative Year-wise Trend, Since 2019
  • Table 20.30 Funding and Investments: Distribution by Type of Funding
  • Table 20.31 Funding and Investments: Distribution by Year and Type of Funding, Since 2019
  • Table 20.32 Funding and Investments: Distribution by Amount Invested, Since 2019 (USD Million)
  • Table 20.33 Funding and Investments: Distribution of Amount Invested by Type of Funding (USD Million)
  • Table 20.34 Funding and Investments: Distribution by Geography (Region)
  • Table 20.35 Most Active Players: Distribution by Number of Funding Instances
  • Table 20.36 Most Active Players: Distribution by Amount Raised (USD Million)
  • Table 20.37 Leading Investors: Distribution by Number of Funding Instances
  • Table 20.38 Funding and Investment Summary, Since 2019 (USD Million)
  • Table 20.39 Global Demand for Neurovascular Devices, till 2035 (Million Units)
  • Table 20.40 Global Demand for Neurovascular Devices: Distribution by Type of Device, till 2035 (Million Units)
  • Table 20.41 Global Demand for Neurovascular Devices: Distribution by Therapeutic Application, till 2035 (Million Units)
  • Table 20.42 Global Demand for Neurovascular Devices: Distribution by Key Geographical regions, till 2035 (Million Units)
  • Table 20.43 Global Neurovascular Devices Market, till 2035 (USD Million)
  • Table 20.44 Global Neurovascular Devices Market, till 2035: Conservative Scenario (USD Million)
  • Table 20.45 Global Neurovascular Devices Market, till 2035: Optimistic Scenario (USD Million)
  • Table 20.46 Neurovascular Devices Market: Distribution by Type of Device, 2019, current year and 2035
  • Table 20.47 Neurovascular Devices Market for Neurothrombectomy Devices, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 20.48 Neurovascular Devices Market for Embolization Devices, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 20.49 Neurovascular Devices Market for Angioplasty Devices, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 20.50 Neurovascular Devices Market: Distribution by Therapeutic Application, 2019, current year and 2035
  • Table 20.51 Neurovascular Devices Market for Ischemic Stroke, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 20.52 Neurovascular Devices Market for Aneurysm, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 20.53 Neurovascular Devices Market for Stenosis, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 20.54 Neurovascular Devices Market for Arteriovenous Malformations (AVMs), till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 20.55 Neurovascular Devices Market: Distribution by End-users, 2019, current year and 2035
  • Table 20.56 Neurovascular Devices Market for Hospitals and Specialty Clinics, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 20.57 Neurovascular Devices Market for Ambulatory Care Centers, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 20.58 Neurovascular Devices Market for Other End-users, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 20.59 Neurovascular Devices Market: Distribution by Key Geographical Regions, 2019, current year and 2035
  • Table 20.60 Neurovascular Devices Market in North America, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 20.61 Neurovascular Devices Market in Europe, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 20.62 Neurovascular Devices Market in Asia-Pacific, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 20.63 Neurovascular Devices Market in Middle East and North Africa, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 20.64 Neurovascular Devices Market in Latin America, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 20.65 Neurovascular Devices Market: Distribution by Key Leading Players

List of Figures

  • Figure 2.1 Research Methodology: Project Methodology
  • Figure 2.2 Research Methodology: Forecast Methodology
  • Figure 2.3 Research Methodology: Robust Quality Control
  • Figure 2.4 Research Methodology: Key Market Segmentation
  • Figure 3.1 Lessons Learnt from Past Recessions
  • Figure 4.1 Executive Summary: Market Landscape
  • Figure 4.2 Executive Summary: Partnerships and Collaborations
  • Figure 4.3 Executive Summary: Funding and Investments
  • Figure 4.4 Executive Summary: Demand Analysis
  • Figure 4.5 Executive Summary: Market Forecast and Opportunity Analysis
  • Figure 5.1 Preventive Measures for Neurovascular Disorders
  • Figure 5.2 Historical Milestones in the Neurovascular Disorders Treatment
  • Figure 5.3 Techniques for the treatment of Neurovascular Disorders
  • Figure 5.4 Types of Neurovascular Devices
  • Figure 5.5 Challenges Associated with Neurovascular Devices
  • Figure 6.1 Neurovascular Devices: Distribution by Status of Development
  • Figure 6.2 Neurovascular Devices: Distribution by Type of Device
  • Figure 6.3 Neurovascular Devices: Distribution by Therapeutic Application
  • Figure 6.4 Neurovascular Devices: Distribution by Type of Device and Therapeutic Application
  • Figure 6.5 Neurovascular Devices: Distribution by Material of Fabrication
  • Figure 6.6 Neurovascular Devices: Distribution by Coating Material of Device
  • Figure 6.7 Neurovascular Device Developers: Distribution by Year of Establishment
  • Figure 6.8 Neurovascular Device Developers: Distribution by Company Size
  • Figure 6.9 Neurovascular Device Developers: Distribution by Location of Headquarters (Region)
  • Figure 6.10 Neurovascular Device Developers: Distribution by Location of Headquarters (Country)
  • Figure 6.11 Neurovascular Device Developers: Distribution by Company Size and Location of Headquarters (Region)
  • Figure 6.12 Most Active Developers: Distribution by Number of Neurovascular Devices Developed
  • Figure 7.1 Johnson & Johnson: Annual Revenues, FY 2020 Onwards (USD Million)
  • Figure 7.2 Medtronic: Annual Revenues, FY 2020 Onwards (USD Billion)
  • Figure 7.3 MicroVention: Annual Revenues, FY 2020 Onwards (Yen Billion)
  • Figure 7.4 Penumbra: Annual Revenues, FY 2019 Onwards (USD Million)
  • Figure 7.5 Stryker: Annual Revenues, FY 2019 Onwards (USD Billion)
  • Figure 8.1 Product Competitiveness Analysis: Neurovascular Devices Developed by Players Based in North America
  • Figure 8.2 Product Competitiveness Analysis: Neurovascular Devices Developed by Players Based in Europe
  • Figure 8.3 Product Competitiveness Analysis: Neurovascular Devices Developed by Players Based in Asia-Pacific and Rest of The World
  • Figure 9.1 Partnerships and Collaborations: Cumulative Year-wise Trend, Since 2019
  • Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 9.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership, Since 2019
  • Figure 9.4 Partnerships and Collaborations: Distribution by Type of Partner
  • Figure 9.5 Partnerships and Collaborations: Distribution by Year and Type of Partner, Since 2019
  • Figure 9.6 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
  • Figure 9.7 Partnerships and Collaborations: Distribution by Type of Device
  • Figure 9.8 Partnerships and Collaborations: Distribution by Therapeutic Application
  • Figure 9.9 Most Active Players: Distribution by Number of Partnerships
  • Figure 9.10 Partnerships and Collaborations: Local and International Agreements
  • Figure 9.11 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
  • Figure 10.1 Funding and Investments: Cumulative Year-wise Trend, Since 2019
  • Figure 10.2 Funding and Investments: Distribution by Type of Funding
  • Figure 10.3 Funding and Investments: Distribution by Year and Type of Funding, Since 2019
  • Figure 10.4 Funding and Investments: Distribution by Amount Invested, Since 2019 (USD Million)
  • Figure 10.5 Funding and Investments: Distribution of Amount Invested by Type of Funding (USD Million)
  • Figure 10.6 Funding and Investments: Distribution by Geography (Region)
  • Figure 10.7 Most Active Players: Distribution by Number of Funding Instances
  • Figure 10.8 Most Active Players: Distribution by Amount Raised (USD Million)
  • Figure 10.9 Leading Investors: Distribution by Number of Funding Instances
  • Figure 10.10 Funding and Investment Summary, Since 2019 (USD Million)
  • Figure 11.1 Global Demand for Neurovascular Devices, Till 2035(Million Units)
  • Figure 11.2 Global Demand for Neurovascular Devices: Distribution by Type of Device, till 2035 (Million Units)
  • Figure 11.3 Global Demand for Neurovascular Devices: Distribution by Therapeutic Application, till 2035 (Million Units)
  • Figure 11.4 Global Demand for Neurovascular Devices: Distribution by Key Geographical Regions, till 2035 (Million Units)
  • Figure 12.1 Neurovascular Devices; Market Drivers
  • Figure 12.2 Neurovascular Devices; Market Restraints
  • Figure 12.3 Neurovascular Devices; Market Opportunities
  • Figure 13.1 Global Neurovascular Devices Market, till 2035 (USD Billion)
  • Figure 13.2 Global Neurovascular Devices Market, till 2035: Conservative Scenario (USD Billion)
  • Figure 13.3 Global Neurovascular Devices Market, till 2035: Optimistic Scenario (USD Billion)
  • Figure 14.1 Neurovascular Devices Market: Distribution by Type of Device, 2019, current year and 2035
  • Figure 14.2 Neurovascular Devices Market for Neurothrombectomy Devices, till 2035 (USD Million)
  • Figure 14.3 Neurovascular Devices Market for Embolization Devices, till 2035 (USD Million)
  • Figure 14.4 Neurovascular Devices Market for Angioplasty Devices, till 2035(USD Million)
  • Figure 15.1 Neurovascular Devices Market: Distribution by Therapeutic Application, 2019, current year and 2035
  • Figure 15.2 Neurovascular Devices Market for Ischemic Stroke, till 2035 (USD Million)
  • Figure 15.3 Neurovascular Devices Market for Aneurysm, till 2035 (USD Million)
  • Figure 15.4 Neurovascular Devices Market for Stenosis, till 2035 (USD Million)
  • Figure 15.5 Neurovascular Devices Market for Arteriovenous Malformations (AVMs), till 2035 (USD Million)
  • Figure 16.1 Neurovascular Devices Market: Distribution by End-users, 2019, current year and 2035
  • Figure 16.2 Neurovascular Devices Market for Hospitals and Specialty Clinics, till 2035 (USD Million)
  • Figure 16.3 Neurovascular Devices Market for Ambulatory Care Centers, till 2035 (USD Million)
  • Figure 16.4 Neurovascular Devices Market for Other End-users, till 2035 (USD Million)
  • Figure 17.1 Neurovascular Devices Market: Distribution by Key Geographical Regions, 2019, current year and 2035
  • Figure 17.2 Neurovascular Devices Market in North America, till 2035 (USD Million)
  • Figure 17.3 Neurovascular Devices Market in Europe, till 2035 (USD Million)
  • Figure 17.4 Neurovascular Devices Market in Asia-Pacific, till 2035 (USD Million)
  • Figure 17.5 Neurovascular Devices Market in Middle East and North Africa, till 2035 (USD Million)
  • Figure 17.6 Neurovascular Devices Market in Latin America, till 2035 (USD Million)
  • Figure 18.1 Neurovascular Devices Market: Distribution by Key Leading Players
  • Figure 19.1 Conclusion: Market Landscape
  • Figure 19.2 Conclusion: Partnerships and Collaborations
  • Figure 19.3 Conclusion: Funding and Investments
  • Figure 19.4 Conclusion: Demand Analysis
  • Figure 19.5 Conclusion: Market Forecast and Opportunity Analysis